Pharmaceuticals
Genscript Biotech Reports 2021 Interim Financial Results
Strong Momentum across All Business Segments, particularly in Gene & Cell Therapy CDMO Continue to accelerate R&D investment to capture Future Growth * Revenue of the Group for the six months ended June 30, 2021 was approximately US$229.6 million, representing an increase of 38.0% as compared...
2021-08-24 01:32
4662
Himalaya Therapeutics Announces Registration of its Office in Shanghai
SHANGHAI and SAN DIEGO, Aug. 23, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization inGreater China, of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, wh...
2021-08-23 22:10
2572
Hepagene Therapeutics, Inc. Announces Positive Results from Phase I Trial of HPG1860
SHANGHAI, Aug. 23, 2021 /PRNewswire/ -- Hepagene Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on novel therapies for patients with liver diseases, today announced positive results from its Phase I study of HPG1860 conducted inthe United States. HPG1860 is a non-bile aci...
2021-08-23 22:00
1924
Study Confirms Viraleze Antiviral Nasal Spray Provides Protection Against SARS-CoV-2 in Challenge Model
MELBOURNE, Australia, Aug. 23, 2021 /PRNewswire/ -- Melbourne biotech company Starpharma has announced the publication of new data demonstrating the capability of its Viraleze antiviral nasal spray to protect against SARS-CoV-2 in an animal challenge model of SARS-CoV-2 infection[1]. Viraleze adm...
2021-08-23 20:23
4925
RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's
U.S. patents for opaganib combination for the treatment of Ebola virus disease provides patent protection until 2035 Opaganib's 475-patient global Phase 2/3 study in severe COVID-19 approaching completion with upcoming top-line results Opaganib also undergoing two oncology Phase 2 U.S. studies a...
2021-08-23 19:00
5089
Everest Medicines to Announce Half-Year 2021 Interim Results
SHANGHAI, Aug. 23, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater China and other parts of Asia, today announced t...
2021-08-23 15:20
4265
Menarini Enters into an Exclusive Licensing Agreement with Daiichi Sankyo to Commercialise TARLIGE(R) in Singapore, Malaysia, and the Philippines
SINGAPORE, Aug. 23, 2021 /PRNewswire/ -- A. Menarini Asia-Pacific Holdings Pte. Ltd., part of the leading Italian global biopharmaceutical company Menarini Group, signed a multi-year exclusive licensing agreement to assume the registration, sales, marketing, and distribution of the orally adminis...
2021-08-23 09:00
2785
Inclusion of Kintor as a Constituent Stock of HSCI
SUZHOU, China, Aug. 23, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company's stock has been included in the Hang Seng Composite ...
2021-08-23 08:44
3961
Ocumension Therapeutics Announces 2021 Interim Results
Company loss narrowed sharply by 96% Business Income Increased By More Than 26 Times Year-on-Year Core Product OT-401 Approval Imminent HONG KONG, Aug. 21, 2021 /PRNewswire/ -- The Chinese ophthalmology platform company,Ocumension Therapeutics ("Ocumension" or the "Company", together with its s...
2021-08-21 00:19
17772
Roche and KeChow Reach a Cooperation Agreement
SHANGHAI, Aug. 20, 2021 /PRNewswire/ -- On August 2, 2021, Shanghai Roche Pharmaceuticals Co., Ltd. (hereinafter referred to as "Roche Pharma China" or "Roche") and Shanghai KeChow Pharma, Inc. (hereinafter referred to as "KeChow Pharma" or "KeChow") entered into a cooperation agreement to improv...
2021-08-20 23:00
3639
CStone Pharmaceuticals Selected as a Constituent of HSCI
SUZHOU, China, Aug. 20, 2021 /PRNewswire/ -- CStone Pharmaceuticals (HKEX: 2616, "CStone" or the "Company"), a leading biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology therapies and precision medicines, announced that the Company has bee...
2021-08-20 20:24
7170
Standigm Expands Global Footprints with New Office in Cambridge, UK
SEOUL, South Korea, Aug. 20, 2021 /PRNewswire/ -- Standigm, a leading workflow AI drug discovery company, today announced the opening of a new office in Cambridge, United Kingdom ("UK"), to accommodate the company's rapid growth in the European market. Founded in 2015, Standigm has proprietary ...
2021-08-20 15:30
1783
Daewoong Pharmaceutical and Hanall Biopharma Invest $1M USD in Alloplex Biotherapeutics
SEOUL, South Korea, Aug. 19, 2021 /PRNewswire/ -- Daewoong Pharmaceutical and
Hanall Biopharma ofSouth Korea are expanding their global open collaboration
initiative by investing in Alloplex Biotherapeutics, an emergingBoston-based
biotechnology company.
2021-08-19 21:00
2986
PharmAbcine Announces Submission of PCT for an Anti-ANG2 Antibody for the Treatment of Ocular Diseases
DAEJEON, South Korea, Aug. 19, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, today announced it submitted a Patent Cooperation Treaty (PCT), an international patent application, for ...
2021-08-19 20:00
1772
I-Mab Announces Establishment of Environmental, Social and Governance Committee
* I-Mab received highest first-time ESG rating among China-based biotech companies from MSCI * New majority independent ESG committee to set overall ESG strategies for the Company * Women account for two-thirds of the total workforce and over 30% of I-Mab's Board of Directors * Committed ...
2021-08-19 19:00
4811
Zhaoke Ophthalmology's Phase III Clinical Trial of Cyclosporine A (CsA) Ophthalmic Gel for Dry Eye Disease Meets Primary Endpoint
Largest Ever Completed Dry Eye Disease (DED) clinical trial to date in China Zhaoke Ophthalmology's in-house developed innovative drug candidate Targeting NDA Filing by the End of 2021 Dry Eye Disease Affects Over 200 Million People in China Potential to become new standard of care for moderate-to-s...
2021-08-19 12:43
4493
Senhwa's Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Recurrent Sonic Hedgehog Driven Medulloblastoma
TAIPEI and SAN DIEGO, Aug. 18, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, today announced that the US Food and Drug Administration (FDA) has granted Fast Tr...
2021-08-19 10:57
2285
MicroConstants to Join BioAgilytix Family
Highly complementary transaction strengthens BioAgilytix's ability to support bioanalytical services across all major therapeutics in development; adds LC/MS/MS capabilities; and expands team of seasoned scientists DURHAM, N.C., Aug. 18, 2021 /PRNewswire/ -- BioAgilytix Labs, LLC (BioAgilytix),...
2021-08-19 02:30
2114
MicroConstants to Join BioAgilytix Family
Highly complementary transaction strengthens BioAgilytix's ability to support bioanalytical services across all major therapeutics in development; adds LC/MS/MS capabilities; and expands team of seasoned scientists DURHAM, N.C., Aug. 19, 2021 /PRNewswire/ -- BioAgilytix Labs, LLC (BioAgilytix), ...
2021-08-19 02:30
2209
Henlius reports half-year (H1) 2021 results, outlines remarkable growth in commercialization and needs-driven innovation
SHANGHAI, Aug. 18, 2021 /PRNewswire/ -- Henlius (2696.HK) announced Half-Year (H1) results endedJune 30th, 2021, sharing the company's recent noteworthy progress and achievements. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innov...
2021-08-18 21:35
4446
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 308 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 290 media titles]
2026-05-18 15:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 280 media titles]
2026-05-20 09:15Most Read
PT Telkom Indonesia (Persero) Tbk 2025 Annual Report on Form 20-F
2026-05-16 00:26
7877
Eyes that photosynthesise: NUS scientists plant a cure for dry eye disease
2026-05-16 11:14
5749
Lepro Introduces STV1, a TV Backlight That Combines Screen Sync, AI Lighting, and Easier Setup
2026-05-16 00:00
5622
NYSE Content Update: Exchange Turns 234 Ahead of U.S. Semiquincentennial
2026-05-18 21:29
5180
NYSE Content Update: Armada Raises $230 Million, Boosts Valuation to $2 Billion
2026-05-19 21:02
5126
